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Abstract
There is compelling evidence implicating intestinal permeability in the pathogen-
esis of nonalcoholic steatohepatitis (NASH), but the underlying mechanisms remain 
poorly understood. Here we examined the role of bile acids (BA) in western diet 
(WD)-induced loss of colonic epithelial barrier (CEB) function in mice with a ge-
netic impairment in intestinal epithelial barrier function, junctional adhesion mol-
ecule A knockout mice, F11r−/−. WD-fed knockout mice developed severe NASH, 
which was associated with increased BA concentration in the cecum and loss of CEB 
function. Analysis of cecal BA composition revealed selective increases in primary 
unconjugated BAs in the WD-fed mice, which correlated with increased abundance 
of microbial taxa linked to BA metabolism. In vitro permeability assays revealed that 
chenodeoxycholic acid (CDCA), which was elevated in the cecum of WD-fed mice, 
increased paracellular permeability, while the BA-binding resin sevelamer hydro-
chloride protected against CDCA-induced loss of barrier function. Sequestration of 
intestinal BAs by in vivo delivery of sevelamer to WD-fed knockout mice attenuated 
colonic mucosal inflammation and improved CEB. Sevelamer also reduced hepatic 
inflammation and fibrosis, and improved metabolic derangements associated with 
NASH. Collectively, these findings highlight a hitherto unappreciated role for BAs 
in WD-induced impairment of the intestinal epithelial barrier in NASH.
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1 |  INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) can be consid-
ered the hepatic manifestation of the metabolic syndrome 
(MetS), which is associated with chronic diseases including 
the type 2 diabetes mellitus (DM), essential hypertension, 
dyslipidemia, obesity, and hypothyroidism.1-3 An estimated 
30%-40% of Americans have increased nonalcohol-related 
free fatty acid (FFA) and triglyceride (TGs) deposition in 
the hepatocytes, termed bland steatosis, or nonalcoholic 
fatty liver (NAFL).4,5 In approximately one-fifth of NAFL 
patients, disease progression can result in nonalcoholic ste-
atohepatitis (NASH), which is characterized by increased 
inflammation and mild to moderate fibrosis. A subset of 
NASH patients is at significantly higher risk of devel-
oping cirrhosis and ultimately hepatocellular carcinoma 
(HCC).1,2 Despite ongoing research, mechanisms leading 
to NAFLD progression remain poorly understood and no 
effective treatment for NASH exists nor do we have a ther-
apy to prevent disease progression.
Recent advances in our understanding of NASH patho-
genesis underscore the contribution of the gut-liver axis 
in NAFLD progression. The concept of gut-liver-axis in 
NAFLD progression emerged from human and animal stud-
ies demonstrating an association between increased intes-
tinal epithelial permeability and serum endotoxin level, a 
potent driver of hepatic inflammation.6-8 We have recently 
demonstrated that western diet (WD) feeding of mice with 
a compromised intestinal epithelial barrier (junctional adhe-
sion molecule A knockout mice, F11r−/−), results in the rapid 
development of steatohepatitis with significant fibrosis.9 
NAFLD progression in this model of compromised intestinal 
epithelial barrier correlated with further increase in intestinal 
epithelial permeability to gut bacterial products as well as 
perturbations in gut microbial composition.9 While this study 
confirmed the role of intestinal epithelial permeability and 
associated microbial dysbiosis in NAFLD progression, the 
mechanisms by which WD compromises intestinal epithelial 
barrier remain unclear.
Bile acids (BA) are amphipathic sterols synthesized 
in the liver from cholesterol, stored in the gall bladder, 
and released in the small intestine postprandially to fa-
cilitate the absorption of dietary fat, cholesterol, and 
fat-soluble vitamins.10,11 BAs secreted into the intestine 
are reabsorbed (~90%-95%) and recirculated to the liver 
via the entero-hepatic circulation. While the majority of 
BA reuptake occurs in the ileum, a small percentage of 
BAs is also reabsorbed in the colon. Colonic absorption 
of BAs is facilitated by gut microbiota, which converts 
the conjugated BAs into more hydrophobic molecules 
to enable their reabsorption by passive diffusion across 
the cell membrane.12-14 The entero-hepatic cycling of 
BAs is a highly efficient and tightly orchestrated process 
that not only provides an effective recycling mechanism 
to conserve and maintain a constant BA pool, but also 
serves as a mechanism to restrict BAs to the intestinal and 
hepatobiliary compartments.15 Disruption of this process, 
primarily due to BA malabsorption or excessive biotrans-
formation by gut microbiota, can increase the passage of 
BAs to the colon.12,16-18 Colonic epithelial cells are sus-
ceptible to BA-induced cytotoxicity, and both in vitro and 
in vivo studies demonstrate that micromolar concentra-
tions of BA can potentially compromise the integrity of 
the intestinal epithelial barrier.19-25 The role of BAs in 
WD-induced loss of intestinal epithelial barrier function 
in NASH is poorly defined, but a recent study reporting 
increased fecal BA concentrations in NASH patients,26 
suggests a role for BAs in promoting colonic epithelial 
permeability in NASH.
The present study was designed to examine the role of 
BA in WD-induced impairment of intestinal epithelial bar-
rier function in WD-fed F11r−/− mice, which develop severe 
steatohepatitis within 8 weeks of feeding a WD.9 Our results 
provide compelling evidence for a novel mechanism whereby 
WD-induced increases in the passage of primary, hydropho-
bic BA, CDCA to the colon compromises colonic epithelial 
barrier. We demonstrate that the BA-binding resin sevelamer 
hydrochloride attenuates NAFLD progression by protecting 
mice from BA-induced loss of colonic epithelial barrier func-
tion. In light of recent reports implicating gut-derived anti-
gens in promoting the progression of NAFL to NASH, our 
findings have important clinical implications for the treat-
ment of NASH.
2 |  MATERIALS AND METHODS
2.1 | Mice
Junctional adhesion molecule A (JAM-A) knock out mice 
(F11r−/−) were generated as previously described.9 Mice 
were bred and maintained at Emory University and the 
University of Pittsburgh Divisions of Animal Resources. All 
animal studies were approved by the Institutional Animal 
Care and Use Committees.
2.2 | BA feeding experiment
C57BL/6 mice were fed CDCA (3mg/gm body weight, 
Millipore Sigma, St. Louis, MO) mixed with FITC-conjugated 
dextran (4 kDa) (0.6 mg/gm body weight, Millipore Sigma, 
St. Louis, MO) solution by oral gavage following a 6 hours 
fast. After 3 hours, blood was collected and fluorescence in-
tensity was measured using Fluorescence Spectrophotometer 
(Synergy 2, BioTek, Winooski, VT) as described previously.9
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2.3 | Diet and feeding studies
Five to six-week-old male F11r−/− mice were fed a ND or 
WD ad libitum for 12 weeks as described previously.9 After 
12 weeks of feeding, mice were fed either ND or WD alone 
(control) or ND or WD mixed with sevelamer hydrochloride 
for 4 weeks. The western diet (WD) consisted of 0.2% cho-
lesterol, 20% protein, 43% CHO, 23% fat (6.6% trans-fat), 
and 2.31% fructose (TD.130885; Harlan Laboratories).9 The 
normal diet (ND) is the standard mouse chow that contains 
16% protein, 61% carbohydrate, and 7.2% fat.
2.4 | Histopathology
Hematoxylin and eosin (H&E) and Sirius Red staining were 
performed on formalin-fixed liver and colon tissue sections, 
as previously reported [4]. A Zeiss Light Microscope (Zeiss, 
Jena, Germany) was employed to obtain the photomicro-
graphs of the histologic sections.
2.5 | Bile acid analysis
Bile acids extracted from liver and cecal content were 
quantified using liquid chromatography-mass spectrometry 
(LC-MS) analysis. Briefly, the liver samples were homog-
enized in PBS and cecal samples were sonicated in PBS. 
Samples were deproteinized with acetonitrile and centri-
fuged; subsequently, the supernatants were lyophilized under 
nitrogen and solvated in a 1:1 (v/v) mixture of methanol and 
water. LC-MS analysis was carried out on the SCIEX 5500 
QTRAP LC-MS system (SCIX, Framingham, MA). Analyses 
of all samples were performed using a C18 reverse-phase 
HPLC column (Thermo Fisher Scientific). MultiQuant 3.0.2 
software was used for the data processing and quantification.
2.6 | Cell culture and in vitro 
permeability assay
Caco2 cells were purchased from American Type Culture 
Collection (ATCC, Manassas, VA). Cells were maintained 
in DMEM supplemented with 10% FBS, 1% penicillin- 
streptomycin, and 1 mmol/L of sodium pyruvate as described 
previously.27
For the in vitro permeability assay, Caco2 cells (passage 
number 23-35) were cultured in 6- or 12-well trans-well cham-
bers (Corning, NY, USA) at a density of 4 × 104 cells/cm2 for 
21 days as described previously.27 Fully differentiated Caco-2 
cell monolayers were treated with 20 μM individual BAs or 
BAs premixed with 0.2 M sevelamer. FITC-conjugated dex-
tran (4 kDa) (Millipore Sigma, St. Louis, MO) dissolved in 
Hanks’ balanced salt solution (HBSS) was added to the apical 
compartment and incubated for 2  hours in a tissue culture 
incubator. CA, CDCA, TCA, and TDCA were dissolved in 
HBSS, while LCA was dissolved in methanol and then diluted 
with HBSS. At the end of the study, transepithelial electrical 
resistance (TEER) was measured using a Millicell-ERS volt-
ohm meter (Millipore, Temecula, CA, USA). Media from 
the basal compartments was collected and fluorescent inten-
sity was measured using Fluorescence Spectrophotometer 
(Synergy 2, BioTek, Winooski, VT). FITC-dextran concen-
trations were determined from a standard curve generated by 
serial dilutions of 4 kDa FITC-dextran.
2.7 | Immunofluorescence microscopy
Liver and intestinal cryosections were stained for immuno-
fluorescence (IF) microscopy as described previously [4]. 
Cryosections were visualized using an Axioskop 2 plus micro-
scope (Zeiss, Jena, Germany). The antibodies used for IF stain-
ing were obtained from Thermo Fisher Scientific (Rockford, IL).
2.8 | Serological analysis
AST and ALT Activity Assay Kits (Sigma-Aldrich, St. Louis, 
MO) were used to estimate serum alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) concentrations.
2.9 | Glucose tolerance test and insulin 
tolerance test
Glucose tolerance test (GTT) and insulin tolerance test (ITT) 
were conducted at 16 weeks of WD feeding, as previously re-
ported [4]. A hand-held glucometer (Freestyle Flash, Abbott 
Laboratories, Abbott Park, IL) was used to determine the 
blood glucose concentration.
2.10 | Quantitative real-time PCR
Total RNA was isolated from the liver, followed by cDNA 
synthesis and qRT-PCR, based on the previously described 
methods [4]. All data were normalized against 18S rRNA and 
were reported as fold change in gene expression as compared 
to those in ND-fed control mice.
2.11 | Statistical analysis
ANOVA, in conjunction with post hoc analysis for multiple 
group comparisons, was used to analyze statistical differences. 
The data reported were from three independent experiments. 
A p value < .05 was considered statistically significant.
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3 |  RESULTS
3.1 | NASH development in WD-fed mice 
is associated with increased BAs in the cecum 
and alterations in the composition of the cecal 
BA pool
To induce NASH, F11r−/− mice were fed a WD for 
16 weeks, F11r−/− mice fed a ND served as controls. WD-
fed F11r−/− mice developed key histological features of 
NASH including hepatic steatosis with increased accumu-
lation of triglycerides in hepatocytes, increased immune 
cell infiltration, and increased fibrosis in the perivascular 
and perisinusoidal regions (Figure  1A,B). Increased colla-
gen deposition in the liver of WD-fed F11r−/− mice corre-
lated with a significant increase in α smooth muscle actin 
(SMA) mRNA transcripts, a key hepatic stellate cell (HSC) 
activation marker,28 as well as mRNA transcripts for tissue 
inhibitors of metalloproteinase (TIMP)-1 and collagen I, 
[αI and αII] (Figure 1B,C-F). Serum aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) levels were also 
significantly higher in WD-fed mice compared to levels 
in the ND-fed mice demonstrating severe hepatic injury in 
these mice (Figure 1G-H).
To determine whether NASH development in WD-fed 
F11r−/− mice was associated with increased passage of BAs 
to the cecum, we quantified total BAs in the cecal content. 
As seen in Figure  1I, the total cecal BA concentration in 
WD-fed mice was twofold higher relative to the ND-fed 
mice. Analysis of the BA composition by liquid chroma-
tography-mass spectrometry (LC-MS) revealed that WD 
consumption increased BAs with high affinity for farne-
soid X receptor (FXR): chenodeoxycholic acid (CDCA), 
cholic acid (CA), lithocholic acid (LCA), as well as BAs, 
that are FXR antagonists: α and β muricholic acid (MCA), 
and urodeoxycholic acid (UDCA) (Figure 1J-K). The con-
centration of conjugated BAs taurocholic acid (TCA), 
taurochenodesoxycholic  acid (TCDCA), and tauroursode-
oxycholic acid (TUDCA) were also significantly higher in 
the WD-fed mice. The colonic BAs in ND-fed mice con-
sisted mainly of primary-unconjugated BAs except for the 
secondary BA deoxycholic acid (DCA). Together, these 
data demonstrate that WD consumption not only increases 
the passage of BAs to the cecum, but also alters the compo-
sition of cecal BA.
3.2 | Sevelamer protects the epithelium from 
BA-induced loss of epithelial barrier
To determine whether the BAs that were increased in the 
cecum of WD-fed mice promoted epithelial permeability, 
we examined the effects of BAs on permeability across 
monolayers of Caco2 cells in vitro, a well-established model 
of human intestinal epithelial barrier function.29 Caco2 cell 
monolayers grown on transwell inserts were treated with 
specific BAs that were differentially represented in the 
cecal content of WD-fed F11r−/− mice and change in per-
meability was determined by the paracellular flux of 4kDa 
FITC-Dextran. As shown in Figure 2A,B, CDCA, but not 
CA, TCA, TDCA or LCA, significantly increased the para-
cellular flux of FITC-dextran. The CDCA-induced increase 
in paracellular permeability correlated with a significant de-
crease in TEER, consistent with CDCA induced the impair-
ment of barrier function in Caco2 cells (Figure 2C,D). To 
determine whether sevelamer, which binds and sequesters 
BAs,30 protects the epithelial barrier from CDCA-induced 
loss of barrier function, we treated Caco2 monolayers with 
CDCA premixed with sevelamer. As shown in Figure 2A,B, 
CDCA premixed with sevelamer did not increase the para-
cellular flux of FITC-dextran across the Caco2 cell mon-
olayers and did not reduce TEER, suggesting that sevelamer 
neutralizes the effect of CDCA on Caco2 monolayers. To 
determine whether CDCA-induced gut permeability in vivo, 
we measured intestinal permeability in CDCA-fed mice 
using the FITC-dextran permeability assay. As shown in 
Figure 2E, oral gavage of CDCA induced a ninefold increase 
in the paracellular flux of 4kDa FITC-Dextran. Together, 
these data suggest that WD-induced increase in the passage 
of CDCA to the cecum of F11r−/− mice impaired colonic 
epithelial barrier.
3.3 | Sequestration of BAs improves 
WD-induced disruption of the colonic 
epithelial barrier
Next, we sought to determine whether the sequestration of 
BAs would protect F11r−/− mice from WD-induced loss of 
colonic epithelial barrier. To address this question, a cohort 
of F11r−/− mice fed a ND or WD for 12-weeks were adminis-
tered sevelamer mixed with diet for an additional four weeks 
(Figure 3A). At the end of the study, we analyzed the respec-
tive BA composition of the cecal contents, which revealed 
a significant increase in BAs in the mice fed a WD mixed 
with sevelamer compared to the cohort of mice fed the WD 
alone; however, no differences in the concentration of total 
BAs were observed between mice fed a ND or ND mixed 
with sevelamer (Figure 3B). Analysis of the composition of 
the BA in the cecal content revealed a significant increase 
in the concentration of CDCA, CA, LCA, TCA TLCA, and 
TCDCA in sevelamer-treated ND and WD fed mice dem-
onstrating that sevelamer sequestered both hydrophobic and 
hydrophilic BAs (Figure 3C).
To determine whether the sequestration of intestinal BAs 
improves colonic epithelial barrier, we examined colonic 
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expression and distribution of the tight junction (TJ) proteins, 
occludin and zonula occludens (ZO)-1 using confocal laser 
scanning microscopy. As evident in the photomicrograph 
(Figure  3D-G and Figure S1A,B), compared with ND fed 
mice, occludin and ZO-1 expression were markedly reduced 
in the colonic mucosa of WD-fed mice. Sevelamer treatment 
restored WD-induced reduction and redistribution of occlu-
din and ZO-1 in the colonic mucosa of mice fed a WD. No 
significant differences in occludin and ZO-1 expression were 
observed between mice fed a ND or ND mixed with seve-
lamer (Figure S1A,B). Together, these data suggest that the 
sequestration of BAs improves WD-induced loss of colonic 
epithelial barrier by restoring the structural integrity of epi-
thelial TJs.
3.4 | Bile acid sequestration attenuates  
WD-induced mucosal inflammation
As seen in Figure 4A and Figure S2A, WD consumption 
resulted in severe colonic mucosal inflammation indicated 
by increased infiltration of immune cells in the mucosa. 
F I G U R E  1  NASH development in western diet-fed mice is associated with increased colonic bile acids. Photomicrographs of A, 
Hematoxylin and Eosin (H&E) and B, Sirius Red stained liver tissue sections of F11r−/− mice fed a normal chow (ND) or western diet (WD) for 
16 weeks (n = 5). Scale bar 20 µm. Black arrowhead, collagen deposition in the liver. C-F, Quantitative reverse transcription PCR analysis of 
hepatic C, α smooth muscle actin (αSMA), D, tissue inhibitor of metalloproteinases (TIMP)-1, E, collagen I αI, and F, collagen I αII transcripts. 
Serum G, ALT and H, AST levels. I, Total bile acid (BA) in the cecal content and J-K, composition of cecal BAs. CDCA, chenodeoxycholic 
acid; CA, cholic acid; MCA, muricholic acid; UDCA, ursodeoxycholic acid; DCA, deoxycholic acid; LCA, lithocholic acid; TCA, taurocholic 
acid; TLCA, taurolithocholic acid; TDCA, taurodeoxycholic acid; TCDCA, taurochenodeoxycholic acid; THDCA, taurohyodeoxycholic acid and 
TUDCA, tauroursodeoxycholic acid. Data are presented as means ± SEM. * P < .05 ND vs WD-fed mice
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Further analysis revealed a marked increase in the infil-
tration of Ly6G + neutrophils and monocytes as well as 
myeloperoxidase (MPO) expressing cells in the colonic 
mucosa of WD-fed F11r−/− mice relative to ND-fed mice 
(Figure 4B,C and Figure S2B-C). The transcript levels of 
proinflammatory cytokines, TNFα, and IL1β were sig-
nificantly higher in the colonic mucosa of WD-fed mice 
relative to the ND-fed mice demonstrating that WD-
consumption resulted in severe mucosal inflammation in 
these mice (Figure 4D,E). The transcript levels of mono-
cyte chemoattractant protein (MCP)-1, C-C chemokine 
receptor (CCR)-2, and F4/80 remained unchanged 
(Figure S2D,F). Sevelamer administration attenuated WD-
induced mucosal inflammation as evident by a marked 
 reduction in immune cell infiltration in the colonic mu-
cosa and a significant decrease in transcript levels of TNFα 
(Figure  4A-D). Levels of IL1β, however, remained un-
changed (Figure 4E).
3.5 | Sequestration of intestinal BAs 
attenuates hepatic inflammation and fibrosis in 
WD-fed mice
To determine whether the administration of sevelamer im-
proved NASH, we examined histological and biochemical fea-
tures of NASH in sevelamer-treated WD-fed F11r−/− mice. In 
agreement with a recent study,31 sevelamer markedly reduced 
hepatic steatosis, inflammation, and fibrosis in the WD-fed 
mice (Figure 5A-P and Figure S3A-C). Improvement in hepatic 
inflammation in sevelamer-treated WD-fed mice was con-
firmed by a significant reduction in serum AST and ALT levels 
(Figure 5B,C), and reduction in hepatic TNFα, IL1β, and IL6 
levels (Figure 5D-F). Administration of sevelamer significantly 
decreased mRNA transcripts of αSMA, TIMP-1, and collagen 
I [αI and αII] (Figure  5H-K) demonstrating a significant re-
duction in HSC activation and collagen deposition in WD-fed 
mice. Sevelamer treatment also reduced hepatic macrophage 
F I G U R E  2  Sevelamer protects epithelial barrier from bile acid-induced increase in paracellular permeability. A,B, Paracellular 
flux of 4 kDa FITC-Dextran across a Caco2 monolayer treated with individual bile acid (BAs) or BAs mixed with sevelamer (Sev). Fully 
differentiated Caco-2 cell monolayers were treated with individual BAs or BAs premixed with sevelamer for 2 hours in the presence of 
4 kDa FITC-Dextran. FITC-dextran flux was determined by measuring the fluorescence intensity of media in the basal chamber. C-D, 
Transepithelial electrical resistance (TEER) of Caco2 monolayers treated with individual BAs or BAs mixed with sevelamer. TEER 
was measured before adding BAs and again after 2-hours incubation. TEER readings are reported as the normalized values after 2-hours 
incubation. E, Fold change in the intestinal permeability to FITC-dextran in control and CDCA-fed mice (n = 3-4 mice per cohort). CA, 
cholic acid; CDCA, chenodeoxycholic acid; TCA, taurocholic acid; TDCA, taurodeoxycholic acid; and LCA, lithocholic acid. Data are 
representative means ± SEM of at least four individual monolayer inserts. *P < .05 HBSS or methanol vs BA-treated wells. #P < .05 BA vs 
BA plus sevelamer-treated wells
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infiltration (Figure 5L and Figure S3C), which correlated with 
a significant decrease in F4/80, MCP-1, CD68, and CCR2 tran-
scripts. Together, these data demonstrate that the administration 
of sevelamer not only attenuated hepatic steatosis and inflam-
mation, but also ameliorated hepatic fibrosis in WD-fed mice.
3.6 | Sequestration of intestinal BAs improves 
metabolic parameters in WD-fed mice
Examination of metabolic parameters in sevelamer-treated 
mice revealed a significant reduction in body weight in 
WD-fed F11r−/− mice, but not in ND-fed mice (Figure 6A). 
Reduction in body weight was most significant in the first 
2  weeks of treatment, after which body weight of seve-
lamer-treated WD-fed mice remained stable (Figure  6A). 
Sevelamer treatment significantly decreased liver weight/
body weight and visceral fat weight/body weight ratios, 
respectively (Figure  6B,C). While sevelamer treatment 
reduced the liver weights of WD-fed mice compared to 
the ND-fed mice, visceral fat weight remained higher 
(Figure  6B,C) in the former. Even after 4  weeks of seve-
lamer treatment, the visceral fat weight of WD-fed mice re-
mained twofold higher than the ND-fed mice (Figure 6C). 
F I G U R E  3  Sequestration of 
intestinal bile acids improves epithelial 
barrier in western diet-fed mice. A, Study 
design. Mice were fed a normal chow 
(ND) or western diet (WD) for 12 weeks 
followed by either the ND or WD with or 
without sevelamer (Sev) for an additional 
4 weeks (n = 5 mice per cohort). B, Total 
bile acid (BA) in the cecal content, and 
C, composition of cecal BAs. CDCA, 
chenodeoxycholic acid; CA, cholic 
acid; MCA, muricholic acid; UDCA, 
ursodeoxycholic acid; DCA, deoxycholic 
acid; LCA, lithocholic acid; TCA, 
taurocholic acid; TLCA, taurolithocholic 
acid; TDCA, taurodeoxycholic acid; 
TCDCA, taurochenodeoxycholic acid; 
THDCA, taurohyodeoxycholic acid and 
TUDCA, tauroursodeoxycholic acid. 
Data are presented as means ± SEM. 
*P < .05 ND vs WD fed mice. #P < .05 
between control and sevelamer-treated mice. 
D-G, Confocal microscopic images with 
quantification of D-E, occludin and F-G, 
ZO-1 immunofluorescence in the colonic 
tissue. Scale bar 20 µm
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We observed improved metabolic parameters in sevelamer-
treated WD-fed mice including  improved glycemic control 
and insulin sensitivity (Figure 6A-E). We observed no sig-
nificant differences in metabolic parameters between mice 
fed a ND or ND and sevelamer (Figure 6A-E). Sevelamer 
treatment significantly reduced serum cholesterol levels to 
levels comparable to those recorded in the ND-fed mouse 
cohort (Figure 6F), suggesting that the sequestration of in-
testinal BA improves whole body cholesterol metabolism in 
WD-fed mice. Sevelamer treatment also reduced hepatic fat 
deposition in the WD-fed mice (Figure 6G). No differences 
in average calorie intake were observed between control and 
sevelamer-treated WD-fed mice (Figure 6H).
3.7 | Intestinal BA sequestration reverses 
WD-induced alteration in hepatic BA 
composition and increases hepatic BA synthesis
To understand the mechanism of sevelamer-mediated im-
provement in metabolic parameters, we examined hepatic 
BA composition in sevelamer-treated WD-fed F11r−/− mice. 
As shown in Figure 7A-B, WD consumption did not increase 
total BA concentrations in the liver; rather, it altered hepatic 
BA composition. WD consumption significantly increased 
TCDCA, but decreased the TDCA in the liver (Figure 7B). 
Sevelamer treatment did not change the total BA concen-
tration in the liver, but decreased βMCA concentration and 
restored TCDCA concentrations to that seen in the livers 
of ND-fed mice (Figure 7A,B). To understand the effect of 
sevelamer on hepatic BA synthesis, we analyzed key en-
zymes that regulate BA biosynthesis in the liver. As shown in 
Figure 7C-E, sevelamer treatment significantly increased the 
expression of key enzymes involved in the classical and al-
ternative BA synthesis pathways, cholesterol 7α-hydroxylase 
(CYP7A1), sterol 27-hydroxylase (CYP27A1), and oxysterol 
7α-hydroxylase (CYP7B1) transcripts. Together, these data 
suggest that the sequestration of BAs activates both classic 
and alternative BA synthesis pathways in the liver without 
altering hepatic BA pool size.
3.8 | WD increases the abundance of 
microbial taxa associated with BA metabolism
Since microbiota play a significant role in metabolism, and 
the absorption and excretion of BAs,32 we analyzed cecal 
mucosa-associated microbiota by 16S rRNA sequencing 
followed by phylogenetic analyses and a comparison of 
the microbial community structure using the unweighted 
UniFrac algorithm as described previously.9 As seen in 
Figure  8A,B, WD consumption decreased diversity and 
F I G U R E  4  Intestinal bile acid sequestration attenuates western diet-induced mucosal inflammation. A, Photomicrographs of 
Hematoxylin and Eosin (H&E) stained colonic mucosal tissue sections of F11r−/− mice fed a normal chow (ND) or western diet (WD) for 12 weeks 
followed by either the ND or WD with or without sevelamer (Sev) for an additional 4 weeks (n = 5 mice per cohort). Scale bar 20 µm. Black 
arrowhead, immune cell infiltration. B-C, Confocal microscopic images of B, myeloperoxidase (MPO) and C, Ly6G expression in the colonic 
tissue. Scale bar 20 µm. D-E, Quantitative reverse transcription PCR analysis (RT-PCR) of colonic D, TNFα and E, IL1β transcripts. Data are 
presented as means ± SEM. *P < .05 ND vs WD fed mice. #P < .05 control vs sevelamer-treated mice
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altered composition of colonic mucosa-associated microbial 
composition. At the order level, WD consumption resulted 
in the expansion of Bacteroidales and Clostridiales, major 
gut microbial taxa with bile salt hydrolase activity33,34; as 
well as Desulfovibrionales, a bacterial taxa associated with 
colitis35; and Deferribacterales (Figure  8C). At the fam-
ily level, WD increased the abundance of Bacteroidaceae, 
Odoribacteraceae, and Desulfovibrionaceae, but decreased 
S24-7 (Figure  8D). Sevelamer treatment did not signifi-
cantly alter the microbial composition in the ND or WD fed 
mice, except for a significant reduction in the abundance of 
Deferribacteraceae in the WD-fed mice. Together, these data 
suggest a link between increased BA metabolizing bacterial 
taxa in the cecum and increased unconjugated BAs in the 
cecal content of WD-fed mice.
4 |  DISCUSSION
In the present study, we provide a potential mechanistic 
explanation underpinning the loss of intestinal epithelial 
barrier function in NASH by demonstrating that WD-
induced increase in the primary BA, CDCA in the cecum 
disrupts the colonic epithelial barrier in mice that ulti-
mately develop severe NASH. We show that the effect of 
CDCA on colonic mucosa was attenuated by the oral ad-
ministration of the BA-binding resin sevelamer, secondary 
to a marked decrease in hepatic inflammation and fibrosis. 
Collectively our data implicate CDCA as a contributing 
factor in WD-induced loss of colonic epithelial barrier in 
NASH and provide evidence that BA-binding resins may 
represent a promising treatment for NASH. Furthermore, 
hepatic injury in F11r−/− mice following 16 weeks of WD 
consumption recapitulates key physiological, metabolic, 
and histological features of human NASH with fibrosis, 
demonstrating the utility of this accelerated rodent model 
of progressive NASH for preclinical studies.
Under normal physiological conditions, only a small 
amount of BA reaches the colon, where it is metabolized by 
resident microbiota to facilitate reabsorption and excretion in 
the stool. Higher concentrations of BAs in the colon, how-
ever, disrupt colonic epithelial barrier integrity ultimately 
F I G U R E  5  Sequestration of intestinal bile acids protects mice from western diet-induced hepatic inflammation and fibrosis. 
Photomicrographs of A, Hematoxylin and Eosin (H&E) stained liver tissue sections of F11r−/− mice fed a normal chow (ND) or western diet  
(WD) for 12 weeks followed by either the ND or WD with or without sevelamer (Sev) for an additional 4 weeks (n = 5 mice per cohort). Scale  
bar 20 µm. B, C, Serum B, ALT and C, AST levels. D-F, Quantification of hepatic proinflammatory cytokines D, TNFα, E, IL-1β, and F,  
IL-6. Photomicrographs of G, Sirius Red stained liver tissue sections. Scale bar 20 µm. Black arrowhead, collagen deposition in the liver. H-K, 
Quantitative reverse transcription PCR (RT-PCR) analysis of hepatic H, α smooth muscle actin (αSMA), I, tissue inhibitor of metalloproteinase 
(TIMP)-1, J, collagen IαI and K, collagen IαII transcripts. L, Confocal microscopic images of tissue-resident macrophage marker F4/80 expression 
in the liver. Scale bar 20 µm. M-P, RT-PCR analysis of hepatic M, F4/80, N, monocyte chemoattractant protein (MCP)-1, O, CD68, and P, C-C 
chemokine receptor (CCR)-2 transcripts. Data are presented as means ± SEM. *P < .05 ND vs WD fed mice. #P < .05 control vs sevelamer-treated 
mice
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resulting in loss of barrier function.19-22 The extent of BA-
induced cytotoxicity and subsequent tissue injury depends 
on the conjugation status, concentration, and the duration of 
exposure.36 At abnormally high concentrations, BAs disrupt 
cell membranes, cause oxidative/nitrosative stress, and apop-
tosis.23,36,37 In contrast, prolonged exposure to high concen-
trations of BAs results in genomic instability and apoptosis 
resistance, which can lead to the development of cancer.38,39 
Our results demonstrate an association between elevated 
cecal BA levels, including the highly cytotoxic primary BA, 
CDCA, and colonic epithelial injury in WD-fed mice. As 
demonstrated by other investigators, CDCA is a potent in-
ducer of epithelial permeability.21,24,25 This together with our 
data from in vitro permeability assay and in vivo BA-feeding 
study implicate CDCA as a major player in driving intestinal 
epithelial permeability, and ultimately NAFLD progression. 
While CA did not induce epithelial permeability in our in 
vitro permeability assay, CA is well known to be highly cyto-
toxic to intestinal epithelial cells,23 and conceivably chronic 
exposure to a high concentration of CA may contribute to co-
lonic tissue injury. Suggesting that similar mechanisms may 
be at play in human NASH, a recent study reported increased 
F I G U R E  6  Intestinal bile acid sequestration improves metabolic parameters and glucose homeostasis. A, Changes in the body, B, liver, 
and C, visceral fat weight in F11r−/− mice fed a normal chow (ND) or western diet (WD) for 12 weeks followed by either the ND or WD with 
or without sevelamer (Sev) for an additional four weeks (n = 5 mice per cohort). Changes in the liver and visceral fat weights are reported as the 
percent of body weight. D, Glucose, and E, insulin tolerance after 16 weeks of total feeding. F, Changes in the serum cholesterol levels. Confocal 
microscopic images of G, BODIPY (lipids) stained liver tissue sections. Scale bar 20 µm. H, Average daily calorie intake. Data are presented as 
means ± SEM. *P < .05 ND vs WD fed mice. #P < .05 control vs sevelamer-treated mice
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fecal BA concentrations in NASH patients, and interestingly 
NASH patients also present with significantly higher levels 
of CA and CDCA in the stool.26 Collectively, these results 
suggest that diet-induced changes in the composition of the 
cecal BA pool could contribute to increased intestinal epithe-
lial permeability that would promote NAFLD progression to 
NASH with fibrosis.9
Sevelamer hydrochloride has profound BA-binding abil-
ities due to its unique cooperative binding property that en-
ables it to bind more hydrophobic BAs, thereby acting as a 
sink for more BA binding, ultimately leading to net excre-
tion of BAs in the stool.30 A significant sevenfold increase 
in CDCA and threefold increase in CA in the cecum content 
of sevelamer-treated WD-fed mice is a testament to the ef-
fectiveness of sevelamer in sequestering these two cytotoxic 
BAs from the colon. This correlated with a marked reduc-
tion in colonic mucosal inflammation and restoration of the 
colonic epithelial barrier in sevelamer-treated WD-fed mice, 
suggesting that the ability of sevelamer to bind and neutralize 
excess BAs in the colon played a central role in protecting 
the colonic mucosa from the harmful effect of cytotoxic BAs. 
Collectively these data further establish the role of BAs in diet- 
induced impairment of colonic epithelial barrier in NASH.
Microbial metabolism of BAs not only increases the 
diversity and hydrophobicity of the BA pool, but also fa-
cilitates passive absorption and excretion of BAs.12 Most 
gut microbial taxa including Lactobacilli, Bifidobacteria, 
Clostridium, and Bacteroides have bile salt hydrolase ac-
tivity and can deconjugate BAs.33,40,41 BA deconjugation, 
however, prevents the active reuptake of BAs via the ASBT 
transporter responsible for the majority of BA reuptake in 
the terminal ileum resulting in the increased passage of BAs 
to the colon.15 Accordingly, in the absence of bacteria in 
the germ-free or antibiotic-treated mice, BA pool consists 
of primary-conjugated BAs, and fecal excretion of BAs is 
decreased in germ-free mice.32,40 In agreement with these 
findings, an increase in unconjugated BAs in the colon of 
WD-fed mice was associated with increased abundance of 
Clostridium and Bacteroides implicating their potential role 
in increasing unconjugated BAs in the colon of WD-fed 
mice. Likewise, an increase in cecal LCA also correlated 
with higher abundance of Clostridium, which are among a 
F I G U R E  7  Intestinal bile acid sequestration restores western diet-induced alterations in the hepatic BA pool. A, Total hepatic BA content 
and B, composition in mice fed a normal chow (ND) or western diet (WD) for 12 weeks followed by either the ND or WD with or without 
sevelamer (Sev) for an additional four weeks (n = 5 mice per cohort). CDCA, chenodeoxycholic acid; CA, cholic acid; MCA, muricholic acid; 
UDCA, ursodeoxycholic acid; DCA, deoxycholic acid; LCA, lithocholic acid; TCA, taurocholic acid; TLCA, taurolithocholic acid; TDCA, 
taurodeoxycholic acid; TCDCA, taurochenodeoxycholic acid; THDCA, taurohyodeoxycholic acid and TUDCA, tauroursodeoxycholic acid. C-E, 
RT-PCR analysis of C, CYP7A1, D, CYP27A1, and E, CYP7B1 transcripts in the liver. Data are presented as means ± SEM. *P < .05 ND vs WD 
fed mice. #P < .05 control vs sevelamer-treated mice
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small number of intestinal anaerobes with 7-dehydratase ac-
tivity, the enzyme required for the production of DCA and 
LCA.12,33,42 Despite marked improvement in colonic muco-
sal injury in sevelamer-treated mice, sevelamer treatment 
did not significantly alter the abundance of taxa belonging 
to either Clostridium or Bacteroides. An increase in uncon-
jugated BAs in the cecum of sevelamer-treated WD-fed mice 
suggests that the ability of sevelamer to sequester and neu-
tralize the cytotoxic effect of BAs protected mucosa from 
BA-induced injury.
Improvement in metabolic derangements associated 
with NAFLD and NASH in the sevelamer-treated WD-fed 
mice may be explained in part by increased hepatic BA bio-
synthesis, which is the major pathway for catabolizing di-
etary cholesterol and maintaining whole body-cholesterol 
homeostasis.10,11 Increased BA biosynthesis in transgenic 
mice overexpressing CYP7A1, the rate-limiting enzyme in 
hepatic BA biosynthesis, improves metabolic homeostasis, 
high-fat diet-induced obesity, and insulin resistance.43,44 
In agreement with these reports, our data demonstrate a 
significant increase in hepatic CYP7A1 expression, which 
was also associated with a significant decrease in serum 
cholesterol in sevelamer-treated WD-fed mice. Sevelamer 
treatment also increased hepatic CYP27A1 expression in 
the WD-fed mice, suggesting that intestinal BA seques-
tration activates both classic and alternative BA synthesis 
pathways.45,46 A similar improvement in metabolic param-
eters was also observed in apical sodium-dependent bile 
acid transporter (ASBT) inhibitor-treated WD-fed mice 
where the inhibition of intestinal BA reuptake was associ-
ated with increased BA biosynthesis.47 These data suggest 
that the inhibition of intestinal BA reuptake improves met-
abolic parameters by increasing hepatic BA biosynthesis. 
Alternatively, it is possible that the ability of sevelamer to 
bind lipids or alter intestinal lipid absorption via the neu-
tralization of intestinal BAs may also contribute to the im-
provement in metabolic derangements in sevelamer-treated 
WD-fed mice. Since intestinal BA critically regulates 
F I G U R E  8  Western diet increases the abundance of gut microbial taxa associated with bile acid metabolism. A, Microbiota richness and 
diversity in the colonic mucosa in mice fed a normal chow (ND) or western diet (WD) for 12 weeks followed by either the ND or WD with or 
without sevelamer (Sev) for an additional four weeks (n = 3-5 mice per cohort). B, Jackknifed principal coordinate analysis (PCoA) of the un-
weighted UniFrac distance matrix of the colonic mucosa-associated microbiota. Symbols represent data from individual mice color-coded by the 
indicated metadata. The ovals represent clustering by treatment groups. C, Relative abundance of bacterial orders in the colonic mucosa. Bars 
represent individual mice. Labels indicate families with average relative abundances >1% in at least one treatment group. D, Relative abundance 
of mucosa-associated bacterial families significantly altered in WD or WD plus sevelamer-treated mice. Data are presented as means ± SEM. 
*P < .05 ND vs WD fed mice. #P < .05 control vs sevelamer-treated mice
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hepatic BA synthesis and whole-body metabolism,48-50 
further studies are needed to delineate how alterations in 
the composition of the colonic BA pool or sequestration 
of intestinal BAs modulates lipid absorption and intestinal 
BA receptor expression, and to determine their effects on 
hepatic BA synthesis.
The modest outcomes of recent early phase clinical tri-
als for NASH with fibrosis that are examining the efficacy 
of various nuclear hormone receptor modulators, fatty acid 
synthesis inhibitors, anti-apoptotic drugs, anti-fibrotics, and 
immunomodulators, as well as drugs used for T2DM and au-
toimmune diseases, demonstrate the complexity to finding 
effective long-term treatments for NASH.51 There is a sig-
nificant resurgence in interest in BAs as crucial players me-
diating the metabolism of carbohydrates and lipids as well as 
in hepatic inflammation and fibrosis. Therefore, further stud-
ies are needed to fully understand the respective mechanistic 
contributions of BAs not-only with respect to regulation of 
lipid and carbohydrate metabolism, but also with respect to 
intestinal epithelial permeability, cellular injury, and repair, 
as well as hepatic inflammation and fibrosis.
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